In this article:

ProQR (PRQR) Gets a Hold Rating from Stifel Nicolaus

In this article:
In this article:

In a report issued on May 7, Dae Gon Ha from Stifel Nicolaus maintained a Hold rating on ProQR (PRQRResearch Report), with a price target of $1.00. The company’s shares closed last Friday at $0.64, close to its 52-week low of $0.64.

According to TipRanks.com, Ha ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.9% and a 13.3% success rate. Ha covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Applied Genetic Technologies, and Ultragenyx Pharmaceutical.

Currently, the analyst consensus on ProQR is a Moderate Buy with an average price target of $2.60.

See today’s best-performing stocks on TipRanks >>

Based on ProQR’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $239K and GAAP net loss of $18.22 million. In comparison, last year the company had a GAAP net loss of $13.22 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Read More on PRQR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed